CRL · NYSE
Charles River Laboratories International, Inc.
$333.68 -18.04 (-5.13%)
Company overview
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NYSE
- Market cap
- $16.1B
- Employees
- 18,700
- Headquarters
- Wilmington, MA
- Website
- criver.com
- CEO
- James C. Foster
- Listed
- June 23, 2000
- P/E
- -88.90
- Dividend yield
- 0.00%
Company financials
- Revenue
- $4B
- Gross profit
- $1.3B
- Operating income
- $474M
- EBITDA
- $804M
- Net income
- -$185M
- EPS
- -$3.75
- Total assets
- $7.7B
- Total debt
- $3.1B
- Gross margin
- 31.86%
- Net margin
- -4.59%
- Earnings yield
- -1.12%
Showing FY 2025
CRL
1D
NYSE
O339.88H356.35L338.55C351.87+13.33 (+3.94%)Vol1.60M
News